Edwards Lifesciences Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bernard J. Zovighian
- Full Time Employees
- 16,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- One Edwards Way Irvine CA United States 92614
- IPO Date
- Mar 27, 2000
- CIK
- 0001099800
- Website
- edwards.com
- Similar Companies
- Business
- Edwards Lifesciences Corporation is a medical technology company specializing in structural heart disease treatments, primarily manufacturing and marketing surgical heart valve repair and replacement devices, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and hemodynamic monitoring systems. Its core products include the SAPIEN transcatheter heart valve line used in aortic stenosis treatments, the PASCAL transcatheter repair system for mitral and tricuspid valves, the Evoque transcatheter tricuspid valve replacement, and a portfolio of surgical heart valves and accessories. The company also provides advanced tissue technologies under the RESILIA platform and pressure and hemodynamic monitoring devices for critical care applications. Edwards operates globally with manufacturing facilities and commercial operations in the United States, Costa Rica, Dominican Republic, Puerto Rico, Singapore, and Ireland. Founded in 1958, it is headquartered in Irvine, California. Recent major company developments include Edwards' strategic expansion via acquisitions, notably JenaValve Technology and Endotronix, which it acquired for approximately $1.6 billion in 2024 to enhance its structural heart disease portfolio with emerging treatments for aortic regurgitation and heart failure monitoring. In mid-2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billion, reflecting a strategic focus shift to core structural heart innovations. The company continues to advance its product pipeline with upcoming FDA approvals, including the SAPIEN M3 transcatheter mitral valve system projected for early 2026 and the next-generation PASCAL system slated for late 2026. Edwards is also preparing to launch the TRIFORMIS surgical valve for the tricuspid position in the U.S. in the second half of 2026 and expects significant clinical trial milestones in 2026. Its financial outlook remains strong, with projected sales growth of 8-10% for 2026 and ongoing development in structural heart therapies and expanded treatment indications.
Company News
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
Edwards Lifesciences Reports Third Quarter Results
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?
Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
Edwards' Q3 Earnings on the Horizon: What's in the Cards?
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives
Is This the Right Time to Hold EW Stock in Your Portfolio?
FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
Is EW Overvalued? DCF Says Worth $40
Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position
First Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EW
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
Edwards Lifesciences to Host Investor Event in Conjunction With TCT